Variable | Months | ||||
---|---|---|---|---|---|
6 (n = 221) | 12 (n = 176) | 24 (n = 196) | 36 (n = 176) | 48 (n = 147) | |
Results are shown as No (%). | |||||
*For these efficacy measures, 1–3 additional patients were available for analysis. The number of patients at the top of each column indicates the number of patients for whom all six efficacy measures were available at that time point. | |||||
TJC68 = 0* | 40 (18) | 32 (18) | 48 (24) | 43 (24) | 42 (28) |
SJC66 = 0* | 33 (15) | 37 (21) | 52 (26) | 42 (23) | 33 (22) |
CRP <8 mg/l* | 146 (66) | 141 (78) | 144 (73) | 126 (71) | 110 (74) |
ACR70 | 53 (24) | 54 (31) | 64 (33) | 56 (32) | 46 (31) |
DAS <2.6 | 71 (32) | 60 (34) | 74 (38) | 67 (38) | 63 (43) |
HAQ reduction ⩾–0.22 | 179 (81) | 145 (82) | 159 (80) | 141 (80) | 118 (81) |
HAQ = 0 | 33 (14)) | 30 (17) | 42 (21) | 42 (24) | 31 (22) |